Hongxiang Huang

Nanchang, 330006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

KLF5-driven TAZ-FASN signaling reprograms fatty acid metabolism to support Treg differentiation in lung cancer.

KLF5-driven TAZ-FASN signaling reprograms fatty acid metabolism to support Treg differentiation in lung cancer.

Journal: Journal of translational medicine

Published: May 01, 2026

Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance efficacy prognostic factors and microbiome diversity analysis.

Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance efficacy prognostic factors and microbiome diversity analysis.

Journal: Journal of translational medicine

Published: October 24, 2025

Relationship Between the Proportion of CD24+ CD27+ B Cells And Lung Adenocarcinoma: Evidence From Mendelian Randomization And Single-Cell Analyses.

Relationship Between the Proportion of CD24+ CD27+ B Cells And Lung Adenocarcinoma: Evidence From Mendelian Randomization And Single-Cell Analyses.

Journal: Current medicinal chemistry

Published: September 19, 2025

c‑Myc‑regulated RPLP0 via the ROS‑mediated JAK2/STAT3 positive feedback loop facilitates hepatocellular carcinoma malignancy progression.

c‑Myc‑regulated RPLP0 via the ROS‑mediated JAK2/STAT3 positive feedback loop facilitates hepatocellular carcinoma malignancy progression.

Journal: International journal of oncology

Published: June 26, 2025

Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer.

Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer.

Journal: Journal of thoracic disease

Published: June 18, 2025

TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor.

TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor.

Journal: Endocrinology and metabolism (Seoul, Korea)

Published: May 22, 2025

EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review.

EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review.

Journal: Respiratory medicine case reports

Published: October 23, 2024

Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer.

Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer.

Journal: Technology in cancer research & treatment

Published: April 24, 2024

Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report.

Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report.

Journal: Experimental and therapeutic medicine

Published: November 28, 2023

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.

Journal: Future oncology (London, England)

Published: February 13, 2023

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.

Journal: Frontiers in oncology

Published: January 04, 2023

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.

Journal: BMC cancer

Published: February 24, 2022

Showing 1-12 of 12

Last Updated: 09/26/2026